



## MAYNE PHARMA LAUNCHES BUDESONIDE CAPSULES IN THE US

---

**27 October 2016, Adelaide Australia:** Mayne Pharma Group Limited (ASX: MYX) is pleased to announce the launch of a generic version of Entocort® EC (budesonide capsules) 3mg in the United States. Budesonide extended-release capsules are used as a treatment for patients with mild to moderate Crohn's disease and according to IMS Health, US brand and generic sales of budesonide capsules were approximately US\$322 million for the 12 months ending 31 August 2016.

Mayne Pharma's CEO, Mr Scott Richards, said "Today's launch adds another quality product to our on-market portfolio of generic pharmaceuticals. This complex product, which formed part of the recent generic product acquisition from Teva Pharmaceutical Industries Limited and Allergan plc, will ultimately be manufactured at our facility in Salisbury, South Australia. Budesonide capsules will benefit from the investments now underway to expand the Salisbury site's fluid bed processing capacity and potent handling capability."

Mayne Pharma markets more than 50 products and has a growing pipeline of more than 40 generic and branded drug products targeting US markets with IMS sales greater than US\$7 billion. Mayne Pharma expects further product launches over the coming year with 19 product applications pending at the FDA.

### For further information contact:

Lisa Pendlebury +61 419 548 434, [lisa.pendlebury@maynepharma.com](mailto:lisa.pendlebury@maynepharma.com)

### About Mayne Pharma

*Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on applying its drug delivery expertise to commercialise branded and generic pharmaceuticals, providing patients with access to better and more affordable medicines. Mayne Pharma also provides contract development and manufacturing services to more than 100 clients worldwide.*

*Mayne Pharma has a 30-year track record of innovation and success in developing new oral drug delivery systems and these technologies have been successfully commercialised in numerous products that have been marketed around the world.*

*Mayne Pharma has two product development and manufacturing facilities based in Salisbury, Australia and Greenville, USA with expertise in the formulation of complex oral dose forms including highly potent compounds, controlled substances, modified-release products and inherently unstable compounds.*

*Entocort® EC is a registered trademark in the US of Perrigo Pharma International*

